Literature DB >> 11794916

Methylphenidate use for attention deficit hyperactivity disorder in northern Israel--a controversial issue.

Y Fogelman1, E Kahan.   

Abstract

BACKGROUND: The prevalence of attention deficit hyperactivity disorder and its pharmacologic treatment have increased dramatically in the past decade in the United States and Britain. We examined the use of methylphenidate hydrochloride for the treatment of ADHD in children in northern Israel.
METHODS: We evaluated all prescriptions for methylphenidate filled in 1999 for children aged 5-18 years residing in northern Israel who were insured by Clalit Health Services, a health maintenance organization that covers approximately 70% of the population.
RESULTS: Methylphenidate was prescribed to 1.45% of the children in northern Israel in 1999, an increase of 20% in the overall prevalence of methylphenidate use since 1992. Eighty-two percent were boys. The rate of prescription varied widely by type of settlement, from 0.2% in Arab cities and towns to 5.7% in kibbutzim. Primary care physicians wrote 78% of all the prescriptions.
CONCLUSIONS: The increase in methylphenidate use was much smaller in northern Israel than in most other developed regions and countries. More efforts at diagnosis and treatment of attention deficit disorders may need to be directed at Arab populations and those with inadequate medical services.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11794916

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  5 in total

1.  Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period.

Authors:  Yacov Fogelman; Shlomo Vinker; Nir Guy; Ernesto Kahan
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD).

Authors:  Scott H Kollins; Joseph English; Rachel Robinson; Matt Hallyburton; Allan K Chrisman
Journal:  Psychopharmacology (Berl)       Date:  2008-12-23       Impact factor: 4.530

Review 3.  Economic implications of attention-deficit hyperactivity disorder for healthcare systems.

Authors:  Cynthia L Leibson; Kirsten Hall Long
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 4.  Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Authors:  Christopher Steer; Jan Froelich; César A Soutullo; Mats Johnson; Monica Shaw
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

5.  Assessing the diagnostic accuracy of the identification of hyperkinetic disorders following the introduction of government guidelines in England.

Authors:  David M Foreman; Tamsin Ford
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-11-04       Impact factor: 3.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.